Any value of podocyte B7-1 as a biomarker in human MCD and FSGS?

Rubina Novelli, Elena Gagliardini, Barbara Ruggiero, Ariela Benigni, Giuseppe Remuzzi

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) are the most common causes of nephrotic syndrome in children and in young adults. Relapsing MCD carries the risk of severe complications and prolonged immunosuppression, whereas FSGS remains largely untreatable and urgently needs more effective treatments. Recently, induction of B7-1 (CD80), an immune-related protein expressed by antigen-presenting cells, was observed in podocytes of MCD and FSGS patients, suggesting that B7-1 plays a role in the pathogenesis of these diseases, and hence that abatacept, a B7-1 inhibitor, could be a possible treatment. Since previous studies raised serious concerns regarding the reliability of immunohistochemical assays for B7-1 detection and the efficacy of B7-1 inhibitory treatment, we investigated B7-1 podocyte expression in MCD and FSGS patients. Using different primary antibodies and immunohistochemical assays, no significant upregulation of podocyte B7-1 was detected in patients' biopsies compared with controls. To further confirm our findings, we analyzed mice with adriamycin-induced nephropathy, a model of human FSGS, and mice injected with LPS as additional control. Podocyte B7-1 was not observed in mice injected with adriamycin or LPS either. In conclusion, since B7-1 is not induced in podocyte of MCD and FSGS patients, the antiproteinuric action of abatacept, if confirmed, may not be the result of an effect on podocyte B7-1.

Original languageEnglish
Pages (from-to)F335-F341
JournalAmerican Journal of Physiology - Endocrinology and Metabolism
Volume310
Issue number5
DOIs
Publication statusPublished - Mar 1 2016

Fingerprint

Lipoid Nephrosis
Focal Segmental Glomerulosclerosis
Podocytes
Biomarkers
Doxorubicin
Nephrotic Syndrome
Antigen-Presenting Cells
Immunosuppression
Young Adult
Up-Regulation
Therapeutics
Biopsy
Antibodies
Proteins

Keywords

  • B7-1
  • focal segmental glomerulosclerosis
  • minimal change disease
  • podocytes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Any value of podocyte B7-1 as a biomarker in human MCD and FSGS? / Novelli, Rubina; Gagliardini, Elena; Ruggiero, Barbara; Benigni, Ariela; Remuzzi, Giuseppe.

In: American Journal of Physiology - Endocrinology and Metabolism, Vol. 310, No. 5, 01.03.2016, p. F335-F341.

Research output: Contribution to journalArticle

@article{3e2917bc422d4d0a9d5995f8a3d442c0,
title = "Any value of podocyte B7-1 as a biomarker in human MCD and FSGS?",
abstract = "Minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) are the most common causes of nephrotic syndrome in children and in young adults. Relapsing MCD carries the risk of severe complications and prolonged immunosuppression, whereas FSGS remains largely untreatable and urgently needs more effective treatments. Recently, induction of B7-1 (CD80), an immune-related protein expressed by antigen-presenting cells, was observed in podocytes of MCD and FSGS patients, suggesting that B7-1 plays a role in the pathogenesis of these diseases, and hence that abatacept, a B7-1 inhibitor, could be a possible treatment. Since previous studies raised serious concerns regarding the reliability of immunohistochemical assays for B7-1 detection and the efficacy of B7-1 inhibitory treatment, we investigated B7-1 podocyte expression in MCD and FSGS patients. Using different primary antibodies and immunohistochemical assays, no significant upregulation of podocyte B7-1 was detected in patients' biopsies compared with controls. To further confirm our findings, we analyzed mice with adriamycin-induced nephropathy, a model of human FSGS, and mice injected with LPS as additional control. Podocyte B7-1 was not observed in mice injected with adriamycin or LPS either. In conclusion, since B7-1 is not induced in podocyte of MCD and FSGS patients, the antiproteinuric action of abatacept, if confirmed, may not be the result of an effect on podocyte B7-1.",
keywords = "B7-1, focal segmental glomerulosclerosis, minimal change disease, podocytes",
author = "Rubina Novelli and Elena Gagliardini and Barbara Ruggiero and Ariela Benigni and Giuseppe Remuzzi",
year = "2016",
month = "3",
day = "1",
doi = "10.1152/ajprenal.00510.2015",
language = "English",
volume = "310",
pages = "F335--F341",
journal = "American Journal of Physiology",
issn = "0363-6119",
publisher = "American Physiological Society",
number = "5",

}

TY - JOUR

T1 - Any value of podocyte B7-1 as a biomarker in human MCD and FSGS?

AU - Novelli, Rubina

AU - Gagliardini, Elena

AU - Ruggiero, Barbara

AU - Benigni, Ariela

AU - Remuzzi, Giuseppe

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) are the most common causes of nephrotic syndrome in children and in young adults. Relapsing MCD carries the risk of severe complications and prolonged immunosuppression, whereas FSGS remains largely untreatable and urgently needs more effective treatments. Recently, induction of B7-1 (CD80), an immune-related protein expressed by antigen-presenting cells, was observed in podocytes of MCD and FSGS patients, suggesting that B7-1 plays a role in the pathogenesis of these diseases, and hence that abatacept, a B7-1 inhibitor, could be a possible treatment. Since previous studies raised serious concerns regarding the reliability of immunohistochemical assays for B7-1 detection and the efficacy of B7-1 inhibitory treatment, we investigated B7-1 podocyte expression in MCD and FSGS patients. Using different primary antibodies and immunohistochemical assays, no significant upregulation of podocyte B7-1 was detected in patients' biopsies compared with controls. To further confirm our findings, we analyzed mice with adriamycin-induced nephropathy, a model of human FSGS, and mice injected with LPS as additional control. Podocyte B7-1 was not observed in mice injected with adriamycin or LPS either. In conclusion, since B7-1 is not induced in podocyte of MCD and FSGS patients, the antiproteinuric action of abatacept, if confirmed, may not be the result of an effect on podocyte B7-1.

AB - Minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) are the most common causes of nephrotic syndrome in children and in young adults. Relapsing MCD carries the risk of severe complications and prolonged immunosuppression, whereas FSGS remains largely untreatable and urgently needs more effective treatments. Recently, induction of B7-1 (CD80), an immune-related protein expressed by antigen-presenting cells, was observed in podocytes of MCD and FSGS patients, suggesting that B7-1 plays a role in the pathogenesis of these diseases, and hence that abatacept, a B7-1 inhibitor, could be a possible treatment. Since previous studies raised serious concerns regarding the reliability of immunohistochemical assays for B7-1 detection and the efficacy of B7-1 inhibitory treatment, we investigated B7-1 podocyte expression in MCD and FSGS patients. Using different primary antibodies and immunohistochemical assays, no significant upregulation of podocyte B7-1 was detected in patients' biopsies compared with controls. To further confirm our findings, we analyzed mice with adriamycin-induced nephropathy, a model of human FSGS, and mice injected with LPS as additional control. Podocyte B7-1 was not observed in mice injected with adriamycin or LPS either. In conclusion, since B7-1 is not induced in podocyte of MCD and FSGS patients, the antiproteinuric action of abatacept, if confirmed, may not be the result of an effect on podocyte B7-1.

KW - B7-1

KW - focal segmental glomerulosclerosis

KW - minimal change disease

KW - podocytes

UR - http://www.scopus.com/inward/record.url?scp=84979098154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979098154&partnerID=8YFLogxK

U2 - 10.1152/ajprenal.00510.2015

DO - 10.1152/ajprenal.00510.2015

M3 - Article

VL - 310

SP - F335-F341

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0363-6119

IS - 5

ER -